Trials - Repurposed drugs

Our international Linked Clinical Trials initiative (LCT) identifies potential new treatments to slow, stop or reverse Parkinson’s disease by 'repurposing' or repositioning drugs that are approved to treat other conditions. Read more

Linked Clinical Trial selection process

By streamlining our trials we provide a foundation to make accurate comparisons between them to then determine the greatest effect for progression into the clinic. Read more

Regenerative trials - GDNF

Regenerative medicine offers hope for a fundamental cure and continues to make substantial progress in Parkinson's. Read more

Trials pending

Our Linked Clinical Trials committee annually assesses favourable drugs which, in studies, have demonstrated putative disease-modifying action in Parkinson's - we are actively committed to bringing these to trial. Read more

Dopamine Cell Replacement Therapies - Research Updates

When diagnosed, people with Parkinson’s have often had the disease for years and have lost over half of the dopamine producing cells in their brain. Now scientists are searching for a way to replace these nerve cells. Read more

Linked Clinical Trial partnership

We are partnered with the Van Andel Research Institute (VARI) - an independent nonprofit biomedical research and science education organisation - for our Linked Clinical Trials programme. Read more